Use of 852A in Metastatic Cutaneous Melanoma.
Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.
Melanoma|Unresectable Metatstatic Cutaneous Melanoma
DRUG: 852A
assessing antitumor activity of 852A intravenous bolus injection administered 3 times a week for 12 weeks
to assess the safety of the dosage regiment over 12 weeks|to obtain preliminary data regarding the safety and long term efficacy of 852A in subjects treated with the drug for more than 12 weeks
Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.